Sava Infond d.o.o. Acquires Shares of 6,100 DexCom, Inc. (NASDAQ:DXCM)

Sava Infond d.o.o. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,100 shares of the medical device company’s stock, valued at approximately $474,000.

Other institutional investors have also recently modified their holdings of the company. Congress Asset Management Co. grew its holdings in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Fisher Funds Management LTD purchased a new position in shares of DexCom during the 4th quarter valued at approximately $96,507,000. Two Sigma Advisers LP grew its stake in DexCom by 182.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after acquiring an additional 739,000 shares during the period. Jennison Associates LLC increased its holdings in DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares in the last quarter. Finally, MIG Capital LLC lifted its holdings in DexCom by 51.5% during the third quarter. MIG Capital LLC now owns 859,627 shares of the medical device company’s stock valued at $57,629,000 after purchasing an additional 292,127 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Citigroup lifted their price target on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Price Performance

NASDAQ:DXCM opened at $69.47 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $141.99. The stock’s fifty day moving average is $82.65 and its two-hundred day moving average is $77.02. The company has a market capitalization of $27.15 billion, a P/E ratio of 48.58, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.